4N90

Crystal structure of ternary complex of TRAIL, DR5, and Fab fragment from a DR5 agonist antibody


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.3 Å
  • R-Value Free: 0.286 
  • R-Value Work: 0.229 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity.

Graves, J.D.Kordich, J.J.Huang, T.H.Piasecki, J.Bush, T.L.Sullivan, T.Foltz, I.N.Chang, W.Douangpanya, H.Dang, T.O'Neill, J.W.Mallari, R.Zhao, X.Branstetter, D.G.Rossi, J.M.Long, A.M.Huang, X.Holland, P.M.

(2014) Cancer Cell 26: 177-189

  • DOI: 10.1016/j.ccr.2014.04.028

  • PubMed Abstract: 
  • Death receptor agonist therapies have exhibited limited clinical benefit to date. Investigations into why Apo2L/TRAIL and AMG 655 preclinical data were not predictive of clinical response revealed that coadministration of Apo2L/TRAIL with AMG 655 lea ...

    Death receptor agonist therapies have exhibited limited clinical benefit to date. Investigations into why Apo2L/TRAIL and AMG 655 preclinical data were not predictive of clinical response revealed that coadministration of Apo2L/TRAIL with AMG 655 leads to increased antitumor activity in vitro and in vivo. The combination of Apo2L/TRAIL and AMG 655 results in enhanced signaling and can sensitize Apo2L/TRAIL-resistant cells. Structure determination of the Apo2L/TRAIL-DR5-AMG 655 ternary complex illustrates how higher order clustering of DR5 is achieved when both agents are combined. Enhanced agonism generated by combining Apo2L/TRAIL and AMG 655 provides insight into the limited efficacy observed in previous clinical trials and suggests testable hypotheses to reconsider death receptor agonism as a therapeutic strategy.


    Organizational Affiliation

    Department of Oncology Research, Amgen Inc., Seattle, WA 98119, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Tumor necrosis factor receptor superfamily member 10B
R, S, T
126Homo sapiensMutation(s): 0 
Gene Names: TNFRSF10B (DR5, KILLER, TRAILR2, TRICK2, ZTNFR9)
Find proteins for O14763 (Homo sapiens)
Go to Gene View: TNFRSF10B
Go to UniProtKB:  O14763
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
Tumor necrosis factor ligand superfamily member 10
A, B, C
168Homo sapiensMutation(s): 0 
Gene Names: TNFSF10 (APO2L, TRAIL)
Find proteins for P50591 (Homo sapiens)
Go to Gene View: TNFSF10
Go to UniProtKB:  P50591
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
Fab light chain
E, G, I
215N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 4
MoleculeChainsSequence LengthOrganismDetails
Fab heavy chain
D, F, H
224N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
ZN
Query on ZN

Download SDF File 
Download CCD File 
A
ZINC ION
Zn
PTFCDOFLOPIGGS-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.3 Å
  • R-Value Free: 0.286 
  • R-Value Work: 0.229 
  • Space Group: P 61 2 2
Unit Cell:
Length (Å)Angle (°)
a = 152.006α = 90.00
b = 152.006β = 90.00
c = 613.155γ = 120.00
Software Package:
Software NamePurpose
HKL-2000data collection
PHASESphasing
HKL-2000data reduction
HKL-2000data scaling
REFMACrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2013-10-18 
  • Released Date: 2014-09-03 
  • Deposition Author(s): Huang, X.

Revision History 

  • Version 1.0: 2014-09-03
    Type: Initial release